XLXiaokun Li

Xiaokun Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaokun Li has a total of 102 co-authors. Here are the top co-authors by number of shared publications:

  • Yi Shen

    Department of Cardiothoracic Surgery, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, China

    10 shared publications
  • Yang Xu

    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    8 shared publications
  • Yong Yuan

    Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China

    8 shared publications
  • Pinhao Fang

    Department of Thoracic Surgery, Med+X Center for Informatics, West China Hospital, Sichuan University , Chengdu, Sichuan 610041

    6 shared publications
  • Hai Zhou

    Department of Cardiothoracic Surgery, Jingling Hospital, Jingling School of Clinical Medicine, Nanjing Medical University, Nanjing, China

    5 shared publications
  • Jianfeng Zhou

    Department of Thoracic Surgery, Med+X Center for Informatics, West China Hospital, Sichuan University , Chengdu, Sichuan 610041

    5 shared publications

Latest Publications

  • Open Access

    Causal association between PM 2.5 and inflammatory biomarkers: a two-sample Mendelian randomization study

    by Haoxuan Gong, Heqi Yang, Xiaokun Li, Zhicong Fu, Xiaopeng Hu, Yuting Xie, Dongsheng Rui, Dan Cao

  • The Efficacy of Time Interval Between Neoadjuvant Chemoimmunotherapy and Surgery on Outcomes in Oesophageal Squamous Cell Carcinoma

    by Pinhao Fang, Xin Xiao, Jianfeng Zhou, Chengyi Mao, Yushang Yang, Siyuan Luan, Xiaokun Li, Zhiwen Liang, Hanlu Zhang, Yong Yuan

    OBJECTIVES: While neoadjuvant immunotherapy combined with chemotherapy (NICT) has demonstrated promising efficacy in oesophageal squamous cell carcinoma (ESCC), the optimal interval between NICT and surgery remains undefined. This study aims to investigate the impact of this interval on pathological response and survival in ESCC patients. METHODS: Totally, 254 patients with locally advanced ESCC who underwent surgical resection following NICT between September 2020 and January 2024 were retrospectively analysed. Based on the time interval from NICT completion to surgery (TTS), patients were stratified into 2 cohorts: within 8 weeks and exceeding 8 weeks. The association between the TTS and postoperative outcomes and long-term prognosis was evaluated. RESULTS: A total of 254 patients were included in the study: 124 patients underwent surgery within 8 weeks after NICT, while 130 patients had surgery over 8 weeks. Among the patients who underwent surgery over 8 weeks, 31 patients (23.8%) achieved pathological complete response (pCR) and 14 patients (11.3%) who underwent surgery within 8 weeks achieved pCR (P = .009). Long-term survival analysis demonstrated that patients who underwent surgery over 8 weeks had significantly better overall survival (OS) (HR, 0.433; 95% CI, 0.233-0.806; P = .008) and disease-free survival (DFS) (HR, 0.451, 95% CI, 0.272-0.748; P = .002) compared to those who had surgery within 8 weeks. CONCLUSIONS: A prolonged surgical interval exceeding 8 weeks following NICT is significantly associated with an increased rate of pCR. Furthermore, delayed surgical intervention beyond the 8-week threshold demonstrates a potential survival benefit in patients with locally advanced ESCC.


  • Open Access

    Editorial: The role of adjuvant and neoadjuvant therapy in resectable esophageal cancer

    by Xiaokun Li, ZhuangZhuang Cong, Yong Qiang

    According to GLOBOCAN data from 2020, esophageal cancer in China ranks fifth among all malignant tumors in terms of incidence, with as many as 324,000 new cases and 301,000 annual deaths [1]. These figures indicate that the burden of esophageal cancer in China is quite heavy, accounting for 55% of global esophageal cancer cases. Unlike Western countries, esophageal cancer patients in China are mainly affected by squamous cell carcinoma, and 40% of patients are already in the advanced stage when they seek medical treatment [2]. For patients with locally advanced esophageal cancer, surgery is a key treatment method, but patients with locally advanced esophageal cancer may achieve better clinical outcomes when undergoing surgery after neoadjuvant therapy. However, the prognosis of these patients remains relatively poor. Between 2009 and 2015, the overall 5-year relative survival rate for esophageal cancer was 21.4%. Specifically, the 5-year relative survival rate for local tumors was 46.7%, for regional metastasis it was 25.1%, and for distant metastasis, it was only 4.8% [3]. The CROSS study is a randomized controlled trial with a duration of over 10 years, whose results have clearly demonstrated that neoadjuvant chemoradiotherapy offers a significant survival advantage over surgery alone in the treatment of locally advanced esophageal cancer. According to this study, the absolute survival benefit for patients within 10 years was 13%. Furthermore, the stratified analysis of pathological types conducted in the study indicated that patients with squamous cell carcinoma derived greater benefits from neoadjuvant chemotherapy compared to those with adenocarcinoma. In the squamous cell carcinoma subgroup, the median overall survival of patients who received preoperative concurrent chemoradiotherapy combined with surgery reached 82 months, while the overall survival of the control group that underwent surgery alone was 21 months [4]. In recent years, immunotherapy (anti-PD-1/PD-L1 therapy) has shown broad application prospects in the neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma, and a large number of studies on chemotherapy combined with immunotherapy have followed. The commonly used chemo-immunotherapeutic drugs mainly include paclitaxel or nab-paclitaxel, platinum-based drugs, anti-PD-1 or anti-PD-L1 antibodies. Recently, the phase III clinical study published by Professor Yin Li's team has landmark significance for neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma [5]. Their study evaluated the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy followed by adjuvant camrelizumab, compared with neoadjuvant chemotherapy alone. A total of 391 patients with resectable thoracic locally advanced esophageal squamous cell carcinoma were enrolled and randomized in a 1:1:1 ratio to receive two cycles of neoadjuvant therapy. The treatment regimens included: camrelizumab + nab-paclitaxel + cisplatin (Cam+nab-TP group, n=132); camrelizumab + paclitaxel + cisplatin (Cam+TP group, n=130); and paclitaxel + cisplatin (TP group, n=129), followed by surgical resection in all groups. The results showed that the Cam+nab-TP and Cam+TP groups exhibited significantly higher pathological complete response (pCR) rates of 28.0% and 15.4%, respectively, compared with 4.7% in the TP group. According to a large number of previous clinical research results, it has also been shown that compared with conventional neoadjuvant chemoradiotherapy, neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma has a relatively lower pathological complete response (pCR) rate, but a relatively longer long-term survival time. Therefore, future studies on chemoimmunotherapy can focus on how to improve the pCR rate of the treatment while ensuring the long-term survival time of chemoimmunotherapy. Meanwhile, subsequent studies can also continue to explore the efficacy of different immunotherapeutic agents in neoadjuvant therapy, while identifying treatment-related biomarkers to better achieve individualized treatment. In this research topic, the article by Jiangbo Lin's team showed that patients who achieved pathological complete response (pCR) after neoadjuvant therapy had a higher 3-year recurrence-free survival rate [6]. This also suggests that it is crucial to explore ways to improve the pCR rate of chemoimmunotherapy. Meanwhile, Ning Jiang's team explored the impact of neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy on postoperative safety in locally advanced esophageal squamous cell carcinoma [7]. The team led by Chaoyang Wu explored biomarkers for tumor regression grade in esophageal squamous cell carcinoma patients after neoadjuvant chemoradiotherapy [8]. This also provides a basis for selecting appropriate patients and implementing individualized treatment in the later stage. In general, patients with locally advanced esophageal squamous cell carcinoma can significantly benefit from neoadjuvant therapy. However, how to select treatment regimens, the advantages and disadvantages of different regimens, and the choice of individualized treatment for patients remain the goals to be studied in the future.

  • Open Access

    Substitute or coexistence? Mediastinoscopy-assisted versus thoracoscope-assisted esophagectomy in esophageal cancer: a meta-analysis of perioperative outcomes and long-term survival

    by Pinhao Fang, Jianfeng Zhou, Yixin Liu, Zhiwen Liang, Yushang Yang, Siyuan Luan, Xin Xiao, Xiaokun Li, Hanlu Zhang, Qixin Shang, et al.

    Background: Currently, mediastinoscopy-assisted esophagectomy (MAE) and thoracoscope-assisted esophagectomy (TAE) represent two prevalent forms of minimally invasive esophagectomy extensively employed in the management of esophageal cancer (EC). The aim of this meta-analysis is to assess and compare these two surgical approaches concerning perioperative outcomes and long-term survival, offering valuable insights for refining surgical strategies and enhancing patient outcomes in this field. Methods: Adhering to PRISMA guidelines, the authors systematically searched PubMed, Web of Science, Cochrane Library, Embase, and CNKI databases until 1 March 2024, for studies comparing MAE and TAE. Outcomes of interest included perioperative outcomes (intraoperative outcomes, postoperative recovery, postoperative complications) and survival rates. Statistical analyses were performed using RevMan 5.4, with heterogeneity dictating the use of fixed or random-effects models. Results: A total of 21 relevant studies were finally included. MAE was associated with significantly shorter operation times [mean difference (MD)=−59.58 min, 95% CI: −82.90 to −36.26] and less intraoperative blood loss (MD=−68.34 ml, 95% CI: −130.45 to −6.23). However, MAE resulted in fewer lymph nodes being dissected (MD=−3.50, 95% CI: −6.23 to −0.78). Postoperative recovery was enhanced following MAE, as evidenced by reduced hospital stays and tube times. MAE significantly reduced pulmonary complications [odds ratio (OR)=0.59, 95% CI: 0.44, 0.81] but increased the incidence of recurrent laryngeal nerve injury (OR=1.84, 95% CI: 1.30, 2.60). No significant differences were observed in anastomotic leakage, chylothorax, cardiac complications, wound infections, and gastric retention between MAE and TAE. The long-term survival outcomes showed no statistical difference [hazard ratio (HR)=1.05, 95% CI: 0.71, 1.54]. Conclusions: MAE offers advantages in reducing operation time, blood loss, and specific postoperative complications, particularly pulmonary complications, with a shorter recovery period compared to TAE. However, it poses a higher risk of recurrent laryngeal nerve injury and results in fewer lymph nodes being dissected. No difference in long-term survival was observed, indicating that both techniques have distinct benefits and limitations. These findings underscore the need for personalized surgical approaches in EC treatment, considering individual patient characteristics and tumor specifics.


  • Open Access

    Association between plasma circulating tumor DNA and the prognosis of esophageal cancer patients: a meta-analysis

    by Haowen Zhang, Tao Jin, Yuhao Peng, Siyuan Luan, Xiaokun Li, Xin Xiao, Yong Yuan

    Background: The application of liquid biopsy analysis utilizing circulating tumor DNA (ctDNA) has gained prominence as a biomarker in specific cancer types. Nevertheless, the correlation between ctDNA and the prognostic outcomes of patients with esophageal cancer (EC) remains a subject of controversy. This meta-analysis aims to assess the correlation between ctDNA and the prognosis of EC patients. Methods: The authors systematically explored Embase, PubMed, and the Cochrane Database to identify studies reporting on the prognostic value of ctDNA in EC patients before November 2023. The primary outcome involved the determine of associations between ctDNA with overall survival (OS), disease-free survival (DFS)/recurrence-free survival (RFS), as well asprogression-free survival (PFS) among EC patients. Secondary outcomes encompassed a detailed subgroup analysis in the setting of EC, including parameters such as detection time, histological subtypes, treatment modalities, regions, anatomic locations, and detection methods. Publication bias was assessed utilizing Begg’s test, Egger’s test, and funnel plots. A sensitivity analysis was conducted by systematically excluding individual studies to evaluate the stability of the results. Results: A total of 1203 studies were initially screened, from which 13 studies underwent further analysis, encompassing 604 patients diagnosed with EC. The comprehensive pooled analysis indicated a significant association between the detection of ctDNA and poor OS (HR: 3.65; 95% CI: 1.97–6.75, PPP<0.001). Subgroup analysis showed that ctDNA remained a consistent negative predictor of OS when stratified by different detection time, histological subtypes, regions, anatomic locations, and detection methods. Furthermore, subgroup analysis stratified by regions and study types demonstrated an association between ctDNA detection and poor PFS in EC patients. Conclusion: Our results indicate plasma ctDNA may serve as robust prognostic markers for OS, DFS/RFS, and PFS among EC patients. This finding suggests that plasma ctDNA could offer a highly effective approach for risk stratification and personalized medicine.


  • Self‐Assembled Acid‐Responsive Nanosystem for Synergistic Anti‐Angiogenic/Photothermal/Ferroptosis Therapy against Esophageal Cancer

    by Xiaokun Li, Jiamei Li, Siqin He, Siyuan Luan, Haowen Zhang, Yushang Yang, Xiaoting Chen, Yilong Chen, Jianfeng Zhou, Pinhao Fang, et al.

    Esophageal cancer (EC) treatment via anti‐angiogenic therapy faces challenges due to non‐cytotoxicity and non‐specific biodistribution of the anti‐angiogenic agents. Hence, the quest for a synergistic treatment modality and a targeted delivery approach to effectively address EC has become imperative. In this study, an acid‐responsive release nanosystem (Bev‐IR820@FeIIITA) that involves the conjugation of bevacizumab, an anti‐angiogenic monoclonal antibody, with TA and Fe3+ to form a metal‐phenolic network, followed by loading with the near‐infrared photothermal agent (IR820) to achieve combinational therapy, is designed. The construction of Bev‐IR820@FeIIITA can be realized through a facile self‐assembly process. The Bev‐IR820@FeIIITA exhibits tumor‐targeting capabilities and synergistic therapeutic effects, encompassing anti‐angiogenic therapy, photothermal therapy (PTT), and ferroptosis therapy (FT). Bev‐IR820@FeIIITA exhibits remarkable proficiency in delivering drugs to EC tissue through its pH‐responsive release properties. Consequently, bevacizumab exerts its therapeutic effects by obstructing tumor angiogenesis, thereby impeding tumor growth. Meanwhile, PTT facilitates localized thermal ablation at the tumor site, directly eradicating EC cells. FT synergistically collaborates with PTT, giving rise to the formation of a reactive oxygen species (ROS) storm, subsequently culminating in the demise of EC cells. In summary, this amalgamated treatment modality carries substantial promise for synergistically impeding EC progression and showcases auspicious prospects for future EC treatment.


  • A novel tumor staging system incorporating cN status for stratifying early stage esophageal squamous cell carcinoma patients after trimodal therapy

    by Xiaokun Li, Siyuan Luan, Chi Zhang, Weili Kong, Xin Xiao, Haowen Zhang, Jianfeng Zhou, Yushang Yang, Yang Xu, Yong Qiang, et al.


  • Retracted

    Causal relationship between lung diseases and risk of esophageal cancer: insights from Mendelian randomization

    by Jianfeng Zhou, Pinhao Fang, Zhiwen Liang, Xiaokun Li, Siyuan Luan, Xin Xiao, Yinmin Gu, Qixin Shang, Hanlu Zhang, Yushang Yang, et al.

    An increasing number of cohort studies have indicated a correlation between lung diseases and esophageal cancer, but the exact causal relationship has not been definitively established. Therefore, the objective of this study is to assess the causal relationship between lung diseases and esophageal cancer. Single-nucleotide polymorphisms (SNPs) related to lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and idiopathic pulmonary fibrosis (IPF), along with outcomes data on esophageal cancer, were extracted from public genome-wide association studies (GWAS). A two-sample Mendelian randomization (MR) analysis was then performed using publicly available GWAS data to investigate the potential causal relationship. The effect estimates were primarily calculated using the fixed-effects inverse-variance-weighted method. Totally, 81 SNPs related to asthma among 218,792 participants in GWAS. Based on the primary causal effects model using MR analyses with the inverse variance weighted (IVW) method, asthma was demonstrated a significantly related to the risk of esophageal cancer (OR 1.0006; 95% CI 1.0003-1.0010, p = 0.001), while COPD (OR 1.0306; 95% CI 0.9504-1.1176, p = 0.466), lung cancer (OR 1.0003, 95% CI 0.9998-1.0008, p = 0.305), as well as IPF (OR 0.9999, 95% CI 0.9998-1.0000, p = 0.147), showed no significant correlation with esophageal cancer. The two-sample MR analysis conducted in this study revealed a positive causal relationship between asthma and esophageal cancer. In contrast, esophageal cancer demonstrated no significant correlation with COPD, lung cancer, or IPF. Further large-sample prospective studies are needed to validate these findings and to provide appropriate recommendations regarding esophageal cancer screening among patients with asthma.


  • Open Access

    The Prognostic Value of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma: A Propensity-Matched Study Based on SEER Database

    by Chi Zhang, Qin Wang, Liwen Hu, Zhuangzhuang Cong, Yong Qiang, Fei Xu, Zheng Zhang, Chao Luo, Bingmei Qiu, Xiaokun Li, et al.

    (1) Objectives: The effect of postoperative radiotherapy (PORT) for thymoma and thymic carcinoma remains controversial. This study aimed to investigate the prognostic value of PORT for thymoma and thymic carcinoma in a population-based registry. (2) Methods: This retrospective study used the Surveillance, Epidemiology, and End Results (SEER) database to identify patients diagnosed with thymoma and thymic carcinoma between 2010 and 2019. Propensity score matching was performed to adjust statistical influences between the PORT and non-PORT groups. (3) Results: A total of 2558 patients with thymoma (n = 2138) or thymic carcinoma (n = 420) were included. In the multivariate analysis, PORT was an independent prognostic factor for OS (overall survival; p < 0.001) and CSS (cancer-specific survival; p = 0.001) in thymoma and an independent prognostic factor for OS in thymic carcinoma (p = 0.018). Subgroup analyses revealed that PORT was beneficial to OS and CSS in patients with Masaoka-Koga stage IIB-IV thymoma (OS: IIB, p < 0.001; III-IV, p = 0.005; CSS: IIB, p = 0.015; III-IV, p = 0.002) and stage IIB thymic carcinoma (OS: p = 0.012; CSS: p = 0.029). (4) Conclusion: This propensity-matched analysis identified the prognostic value of PORT in thymoma and thymic carcinoma based on the SEER database. For patients with stage IIB-IV thymoma and stage IIB thymic carcinoma, PORT was associated with improved OS and CSS. A more positive attitude towards the use of PORT for nonlocalized thymoma and thymic carcinoma may be appropriate.


  • Open Access

    Trimodal Therapy in Esophageal Squamous Cell Carcinoma: Role of Adjuvant Therapy Following Neoadjuvant Chemoradiation and Surgery

    by Xiaokun Li, Siyuan Luan, Yushang Yang, Jianfeng Zhou, Qixin Shang, Pinhao Fang, Xin Xiao, Hanlu Zhang, Yong Yuan

    Background: The aim of this study was to determine the role of adjuvant therapy after neoadjuvant chemoradiotherapy and esophagectomy for esophageal squamous cell carcinoma (ESCC). Methods: The study retrospectively reviewed 447 ESCC patients who underwent neoadjuvant chemoradiotherapy and esophagectomy. Patients were divided into an adjuvant therapy group and no adjuvant therapy group. Propensity score matching was used to adjust the confounding factors. Results: 447 patients with clinical positive lymph nodes and no distant metastasis treated with neoadjuvant chemoradiotherapy and esophagectomy were eligible for analysis. After propensity score matching, there were 120 patients remaining in each group. Patients receiving adjuvant therapy had a significantly shorter post-resection overall survival (OS) and disease-free survival (DFS) when compared to patients not receiving adjuvant therapy (log-rank, OS: p = 0.046, DFS: p < 0.001). Receiving adjuvant therapy is not an independently prognostic factor for OS (hazard ratio (HR): 1.270, HR: 0.846–1.906, p = 0.249) but a significantly unfavorable independent prognostic factor for DFS (HR: 2.061, HR: 1.436–2.958, p < 0.001). Conclusions: The results of our study indicate that adjuvant therapy after neoadjuvant chemoradiotherapy and surgery could reduce the OS and DFS in patients with ESCC. Therefore, adjuvant therapy is not recommended for ESCC patients after neoadjuvant chemoradiotherapy and esophagectomy, especially patients without nodal metastases after neoadjuvant therapy.